Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 11/20 | 0.76 |
| ▸ | FYN | P06241 | 4/20 | 0.70 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.70 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.70 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.63 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225807 | 0.86 | MAP4K4 (1.00) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL2227291 | 0.86 | MAP4K4 (0.86) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL2225202 | 0.82 | FYN (1.00) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL30521788 | 0.82 | FYN (1.00) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL2226484 | 0.81 | MAP4K4 (0.78) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL2226014 | 0.81 | MAP4K4 (0.78) | MAP4K4FYNMINK1TNIKKCNH2 | |
| SCHEMBL2223417 | 0.80 | MAP4K4 (0.76) | MAP4K4FYNMINK1TNIKKCNH2 | |
| SCHEMBL2225323 | 0.80 | KCNH2 (0.63) | MAP4K4FYNMINK1TNIKCHEK2 | |
| SCHEMBL2227734 | 0.79 | MAP4K4 (0.75) | MAP4K4FYNMINK1TNIKKCNH2 | |
| SCHEMBL27902096 | 0.79 | CHEK2 (0.62) | MAP4K4FYNMINK1TNIKCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | claimed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | claimed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | claimed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | claimed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | claimed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | claimed |
| CN-102812006-B | Novel antimalaria reagent | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-01-20 | — | — | CN | disclosed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | MAP4K4 1556/4885FYN 3839/4885MINK1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.